Apellis Pharmaceuticals Inc
NASDAQ:APLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
US |
|
Brookfield Wealth Solutions Ltd
TSX:BNT
|
BM |
|
Hooker Furnishings Corp
NASDAQ:HOFT
|
US |
|
Fertilisers And Chemicals Travancore Ltd
NSE:FACT
|
IN |
|
Summit Materials Inc
NYSE:SUM
|
US |
|
M
|
MTN Group Ltd
JSE:MTN
|
ZA |
|
Meta Platforms Inc
NASDAQ:META
|
US |
|
eBay Inc
NASDAQ:EBAY
|
US |
|
J
|
JCDecaux SE
SWB:DCS
|
FR |
|
P
|
Pioneer Property Group ASA
OSE:PPG
|
NO |
|
Steadfast Group Ltd
ASX:SDF
|
AU |
Wall St Price Targets
APLS Price Targets Summary
Apellis Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for APLS is 40.5166 USD with a low forecast of 28.28 USD and a high forecast of 47.25 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is APLS's stock price target?
Price Target
40.5166
USD
According to Wall Street analysts, the average 1-year price target for APLS is 40.5166 USD with a low forecast of 28.28 USD and a high forecast of 47.25 USD.
What is the Revenue forecast for Apellis Pharmaceuticals Inc?
Projected CAGR
9%
The compound annual growth rate for Revenue over the next 8 years is 9%.
What is the Operating Income forecast for Apellis Pharmaceuticals Inc?
Projected CAGR
38%
The compound annual growth rate for Operating Income over the next 8 years is 38%.
What is the Net Income forecast for Apellis Pharmaceuticals Inc?
Projected CAGR
49%
The compound annual growth rate for Net Income over the next 8 years is 49%.
